drugset / Trial / NCT02970643

Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN

NCT02970643

NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to determine whether Palonosetron and Olanzapine without dexamethasone for the Prevention of moderate risk Chemotherapy-Induced Nausea and vomiting.

Timeline

Start
2016-07
Primary completion
2017-09
Completion
2017-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Olanzapine Small molecule 10 mg Oral
Background Palonosetron Other / unclassified 0.25 mg Intravenous